Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Journal of Infection Année : 2000

Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient

Résumé

Chronic active hepatitis B exacerbations have been reported following development of resistance to or withdrawal of lamivudine in HIV-infected patients. A 38-year-old woman with HIV and chronic HBV infections was hospitalized because of acute hepatitis. The occurrence of cytolysis with replication of HBV 2 months after withdrawing lamivudine suggests that our patient experienced a severe reactivation of HBV infection due to the modification of her treatment. Sequencing of the HBV precore region showed the strain to be a mutant. We conclude that lamivudine should not be stopped in HIV- and HBV-infected patients, but could be continued at the dose of 100mg/day as used in isolated HBV infection.

Dates et versions

hal-02014644 , version 1 (11-02-2019)

Identifiants

Citer

D. Neau, Evelyne Schvoerer, D. Robert, F. Dubois, H. Dutronc, et al.. Hepatitis B Exacerbation with a Precore Mutant Virus Following Withdrawal of Lamivudine in a Human Immunodeficiency Virus-infected Patient. Journal of Infection, 2000, 41 (2), pp.192-194. ⟨10.1053/jinf.2000.0724⟩. ⟨hal-02014644⟩

Collections

UNIV-LORRAINE
34 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More